ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.
The agreement will fully leverage ConcertAI's newly launched Translational360™, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.
Translational360™ combines clinical, genomic, transcriptomic, and whole-slide imaging (WSI) from comprehensive molecular testing for deep phenotypical and genomic insights. Transcriptomics is increasingly a foundation of biopharma translational sciences, allowing researchers to understand disease molecular mechanisms, basis of patient response, and inter-patient variability that's essential for developing new therapeutics. Too often, clinical trial results in early phases are ambiguous with idiosyncratic positive and negative responses. The integrated data solutions and advanced AI enable selection of programs with the highest likelihood of success and design trials informed by multi-modal, multi-genomic, and transcriptomic data and AI.
'This partnership furthers causal biological inferences where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster,' said Jeff Elton, Ph.D., CEO of ConcertAI. 'This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modeling of likely success and benefit, informing program priority and clinical study design.'
'As cancer rates continue to rise, we're committed to advancing next-generation solutions that can speed up drug discovery and clinical development, enabling us to bring precision oncology treatments to patients faster,' said Sai Jasti, Head of Data Science and AI for Pharma R&D at Bayer. 'By combining ConcertAI's powerful data solutions with Bayer's scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.'
'More AI-designed new molecular entities are progressing faster in first-in-human trials which is a great milestone,' said Claudio D'Ambrosio, Ph.D., Chief Revenue Officer of ConcertAI. 'Our entire R&D process has been historically built on studying controlled cell lines and animal models that don't reflect the interspecies differences, the physiology, and the different biological barriers we have in humans. We are flipping this paradigm on its head. We need to start with human cancer genomes and phenotypes and 'reverse translate.' Unlike only a few years ago, we now have powerful human data.'
About ConcertAI:
ConcertAI is a leader in predictive and generative AI SaaS and multi-modal real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai ™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, empowering oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Securities Fraud Investigation Into Sable Offshore Corp. (SOC) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Sable Offshore Corp. ('Sable' or the 'Company') (NYSE: SOC) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SABLE OFFSHORE CORP. (SOC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 19, 2025, Sable announced that it had resumed oil production from one of three offshore platforms related for its Las Flores pipelines ('Onshore Pipeline') in California. Then, on May 23, 2025, the California State Land Commission sent Sable a letter regarding its May 19th announcement, warning that it 'appears to mischaracterize the nature of recent activities, causing significant public confusion and raising questions regarding Sable's intentions,' and that Sable had conflated offshore well testing activities required by a federal regulatory agency with the restart of operations. Then, on May 28, 2025, the Santa Barbara County Superior Court approved a preliminary injunction from the California Coastal Commission regarding Sable's maintenance and repair work in the coastal zone related to the Onshore Pipeline. On this news, Sable's stock price fell $5.04, or 15.3%, to close at $27.89 per share on May 28, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Sable securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
26 minutes ago
- Yahoo
Updated Briefing and Discovery Schedule for CITGO Sale Hearing
PEMBROKE, Bermuda, June 11, 2025--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) ("Gold Reserve" or the "Company") announces that the U.S. District Court for the District of Delaware (the "Court") issued an order adopting the following revised schedule for briefing and discovery deadlines proposed by the Special Master given the expiration of the Topping Period on June 18, 2025 and rescheduled start date for the Sale Hearing to August 18, 2025, as previously announced here. Event Deadline Deadline for the Special Master to submit his Final Recommendation July 2 Deadline to serve written discovery on the party (or parties) whose bid is selected as the Final Recommendation July 7 Opening expert reports due July 7 Deadline for the filing of any objections to the Special Master's Final Recommendation July 9 Deadline for any Competing Objector to disclose its own bid materials (such materials to be commensurate with those disclosed by the Special Master of the recommended bid) July 9 Deadline to serve written discovery on a Competing Objector July 11 Deadline to serve responses and objections for discovery requests served after the Final Recommendation July 15 Deadline to meet and confer regarding the scope of discovery to be produced in response to discovery requests served after submission of the Final Recommendation July 16 Deadline to serve witness disclosures pursuant to FRCP 26(a)(3) July 18 Deadline to notice witness depositions July 21 Deadline to serve responsive expert reports July 21 Deadline to complete document productions in response to discovery requests served before the submission of the Final Recommendation and substantially complete document productions in response to discovery requests served after the submission of the Final Recommendation July 22 Deadline to serve reply expert reports, if any July 25 Conclusion of the discovery period July 31 Deadline for the filing of responses to objections to the Special Master's Final Recommendation August 1 Deadline for the filing of replies regarding any objections to the Special Master's Final Recommendation August 8 Deadline for the filing of sur-replies to replies regarding any objections to the Special Master's Final Recommendation (only to the extent new arguments are raised in reply briefing) August 12 Deadline for the Special Master to submit Joint Status Report August 13 Deadline to disclose exhibits pursuant to FRCP 26(a)(3) August 13 Deadline to serve objections to FRCP 26(a)(3) exhibit disclosures August 15 Commencement of the Sale Hearing August 18 A copy of the Court's complete order can be found here. A complete description of the Delaware sale proceedings can be found on the Public Access to Court Electronic Records system in Crystallex International Corporation v. Bolivarian Republic of Venezuela, 1:17-mc-00151-LPS (D. Del.) and its related proceedings. Cautionary Statement Regarding Forward-Looking statements This release contains "forward-looking statements" within the meaning of applicable U.S. federal securities laws and "forward-looking information" within the meaning of applicable Canadian provincial and territorial securities laws and state Gold Reserve's and its management's intentions, hopes, beliefs, expectations or predictions for the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. They are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements contained in this press release include, but are not limited to, statements relating to any bid submitted by the Company for the purchase of the PDVH shares (the "Bid"). We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause the actual events, outcomes or results of Gold Reserve to be materially different from our estimated outcomes, results, performance, or achievements expressed or implied by those forward-looking statements, including but not limited to: the discretion of the Special Master to consider the Bid, to enter into any discussions or negotiation with respect thereto and that the Special Master may reject the Bid at any time; the Special Master may choose not to recommend a Base Bid or Final Bid to the Court; the failure of the Company to negotiate the Bid, including as a result of failing to obtain sufficient equity and/or debt financing; that Bid submitted by the Company will not be selected as the "Base Bid" or the "Final Recommend Bid" under the Bidding Procedures, and if selected may not close due to the Sale Process not being completed, including as a result of not obtaining necessary regulatory approval to close on the purchase of the PDVH shares, including but not limited to any necessary approvals from the U.S. Office of Foreign Asset Control ("OFAC"), the U.S. Committee on Foreign Investment in the United States, the U.S. Federal Trade Commission or the TSX Venture Exchange; failure of the Company or any other party to obtain any required shareholders approvals for, or satisfy other conditions to effect, any transaction resulting from the Bid; that the Company forfeit any cash amount deposit made due to failing to complete the Bid or otherwise; that the making of the Bid or any transaction resulting therefrom may involve unexpected costs, liabilities or delays; that, prior to or as a result of the completion of any transaction contemplated by the Bid, the business of the Company may experience significant disruptions due to transaction related uncertainty, industry conditions, tariff wars or other factors; the ability to enforce the writ of attachment granted to the Company; the timing set for various reports and/or other matters with respect to the Sale Process may not be met; the ability of the Company to otherwise participate in the Sale Process (and related costs associated therewith); the amount, if any, of proceeds associated with the Sale Process; the competing claims of other creditors of Venezuela, PDVSA and the Company, including any interest on such creditors' judgements and any priority afforded thereto; uncertainties with respect to possible settlements between Venezuela and other creditors and the impact of any such settlements on the amount of funds that may be available under the Sale Process; and the proceeds from the Sale Process may not be sufficient to satisfy the amounts outstanding under the Company's September 2014 arbitral award and/or corresponding November 15, 2015 U.S. judgement in full; and the ramifications of bankruptcy with respect to the Sale Process and/or the Company's claims, including as a result of the priority of other claims. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. For a more detailed discussion of the risk factors affecting the Company's business, see the Company's Management's Discussion & Analysis for the year ended December 31, 2024 and other reports that have been filed on SEDAR+ and are available under the Company's profile at Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Gold Reserve or persons acting on its behalf are expressly qualified in their entirety by this notice. Gold Reserve disclaims any intent or obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of assumptions or factors, whether as a result of new information, future events or otherwise, subject to its disclosure obligations under applicable rules promulgated by applicable Canadian provincial and territorial securities laws. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. For further information regarding Dalinar Energy, visit: For further information regarding Gold Reserve Ltd., visit or contact: View source version on Contacts Kathryn Houlden(441) 295-4653A.S. Cooper Building, 7th Floor, 26 Reid Street, Hamilton, HM 11, Bermudainvestorrelations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Ameresco Celebrates the Completion Solar Canopy Project with the City of Pendleton, Oregon
The solar canopy, part of a multiphase infrastructure improvement project, is expected to offset significant energy costs and generate 325,000 kWh of electricity annually FRAMINGHAM, Mass. & PENDLETON, Ore., June 11, 2025--(BUSINESS WIRE)--Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition and the City of Pendleton in Oregon today hosted a ribbon-cutting ceremony to celebrate the completion of a 240-kilowatt (kW) solar photovoltaic (PV) canopy system at the Pendleton Wastewater Treatment and Resource Recovery Facility (WWTRRF). This innovative solar canopy--the first of its kind in the region--represents a major milestone in the City's ongoing efforts to enhance energy resilience, efficiency and innovation, supported by Ameresco. The solar canopy is expected to annually generate 325,000 kilowatt-hours (kWh) of electricity, which will offset approximately 30% of the WWTRRF's total energy consumption. "This project marks a major step forward in our commitment to developing efficient and resilient solutions for our city," said Kyle Willman, Superintendent, at Wastewater Treatment Resource Recovery Facility. "The solar canopy not only helps reduce our energy costs and environmental footprint, but it also enhances the performance of our wastewater treatment facility in ways that benefit the entire community. We're grateful for our partnership with Ameresco and for the state and local support that made this forward-thinking investment possible." In addition to providing on-site energy production and cost savings, the canopy shades the WWTRRF's chlorine contact chamber, helping to improve water quality, reduce effluent temperature and support a healthier aquatic ecosystem. The project is part of a multiphase infrastructure improvement initiative and was delivered through an Energy Savings Performance Contract (ESPC) with Ameresco, who provided price and performance guarantees and helped ensure participation from disadvantaged and local businesses. The Pendleton WWTRRF project was funded through a combination of state grants (including ODOE's C-REP grant), utility incentives and city resources. As part of the City's ongoing efforts to increase the resilience and reliability of the WWTRRF, plans are underway for a future battery energy storage system (BESS) to complement the solar canopy and further decrease the operational costs of the facility. "We are proud to partner with the City of Pendleton in its mission to build a resilient future," said Lou Maltezos, President of Central & Western USA, Canada Regions at Ameresco. "This solar canopy project is a great example of how innovative energy solutions can deliver meaningful economic benefits and support essential city infrastructure. We're not only improving operational efficiency but also contributing to the health of the local ecosystem and empowering the community with long-term energy savings." For more information about Ameresco and its energy efficiency and resiliency infrastructure solutions, visit About Ameresco, Inc. Founded in 2000, Ameresco, Inc. (NYSE: AMRC) is a leading energy solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering diversified generation solutions to Federal, state and local governments, utilities, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit About the City of Pendleton The City of Pendleton is a vibrant and active community with a rich heritage and a lively history. Located at the base of the Blue Mountains in Eastern Oregon, Pendleton is well known for its world-class Pendleton Round-Up rodeo, a thriving arts culture and many historic attractions. To learn more, visit The announcement of completion of a customer's project contract is not necessarily indicative of the timing or amount of revenue from such contract, of Ameresco's overall revenue for any particular period or of trends in Ameresco's overall total project backlog. This project was included in Ameresco's previously reported contracted backlog as of March 31, 2025. View source version on Contacts Media: Ameresco: Leila Dillon, 508-661-2264, news@
